Skip to content

DCS as an enhancer of ERP in panic disorder and OCD.

D-cycloserine enhancement of exposure and response prevention therapy in OCD and panic disorder with agorphobia: a randomised controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25942
Enrollment
120
Registered
2009-10-11
Start date
2010-01-02
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic disorder with agoraphobia, and obsessive-compulsive disorder are studied using DCS either before or afer exposure with response prevention sessions.

Interventions

Both study groups n=60 (OCD and n=60 panic disorder+ agorphobia patients) receive 12 ERP standard sessions, and in the first 6 sessions they receive study medication either directly pre or post sessio

Sponsors

Utrecht University, department of clinical psychology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A DSM IV diagnosis of panic disorder with agoraphobia, or obsessive-compulsive disorder.

Exclusion criteria

Exclusion criteria: 1. Mental deficiency; 2. Inability to speak or read Dutch; 3. Severe co-morbid psychiatric diagnoses.

Design outcomes

Primary

MeasureTime frame
in Panic disorder+agorphobia: the Mobility Inventroy (Chambless, 1985). In OCD: the YBOCS severity scale (Goodman, 1989).

Secondary

MeasureTime frame
In both patient groups, the following measures will be taken at baseline, mid-treatment,at post-test and FU: 1. Beck Anxiety Inventory (BAI; Beck, 1990), on global anxiety severity; 2. Clinical Global Impression (CGI; Guy, 1976); 3. Hamilton Depression Rating Scale (HDRS; Hamilton, 1960); 4. Hamilton Anxiety Rating Scale (HARS;Hamilton, 1960); 5. Sheehan Disability Scales (SDS; Sheehan, 1998); 6. WHOQOL (Quality of Life; WHOQOL Group, 1996); 7. The Fawcett side effects checklist (Fawcett, 1987); 8. In PD+AGO, the Panic disorder severity scale (Shear, 1997; measures panic symptom severity),the Body Symptoms Questionnaire (BSQ; Chambless,1985; measures physiological panic symptoms, and the Agoraphobic Cognitions Questionnaire (ACQ; Chambless, 1985) is taken at baseline, post-test and FU; 9. In OCD, the Dutch Dimensional Obsessive Compulsive Scale (DDOCS; Denys et al.2005), and the Brown assessment of Belief Scale (BABS; Eisen et al, 1998) are taken at baseline, and at posttest and FU. 31-aug-2014: For the OCD population, we made no changes in primary outcome measure (Y-BOCS), but we used these secondary outcome measures: CGI, HDRS, HARS, SDS, WHOQOL, TicP and MOS-SF (instead of the original described secondary outcome measures: BAI, CGI, HDRS, HARS, SDS, WHOQOL, Tic-P, Fawcett, DDOCS and BABS). For the panic disorder population, we made no changes in primary outcome measure (Mobility Inventory), but we used these secondary outcome measures: BAI, PDSS, SUDS, BDI, WHOQOL, Fawcett and Tic-P (instead of the original described secondary outcome measures: BAI,PDSS,SUDS, CGI,HDRS, HARS, SDS, WHOQOL, Tic-P, Fawcett, BSQ and ACQ).

Contacts

Public ContactG. Boois, de

Utrecht university, department of clinical psychology PO BOx 80140

G.de.boois@uu.nl-

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)